No image available for this title

LITERATURE

Breast Cancer: High-Dose Therapy


Breast cancer has become the leading indication for high-dose chemotherapy (HDC) with autologous stem cell rescue (ASCR) in North America. The rapid increase in HDC/ASCR for breast cancer has been driven by belief in the response rates and survival times demonstrated in phase II studies, which
have been higher than that of historical controls. However, there is a growing body of data to suggest that selection bias has had a significant impact on the
outcome of non-randomized studies of HDC. Few randomized comparisons of HDC to standard-dose chemotherapy exist.


Availability

Epirubicin-001Available

Detail Information

Series Title
-
Call Number
-
Publisher : .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Specific Detail Info
The Oncologist 1998;3:289-299
Statement of Responsibility

Other version/related

No other version available


File Attachment



Information


RECORD DETAIL


Back To Previous